Home Business Life Sciences and Bio Pharma Indegene Acquires BioPharm to ...

Indegene Acquires BioPharm to Boost AI-Powered Pharma Marketing

Life Sciences and Bio Pharma

BusinessHonor - Indegene Acquires BioPharm for AI Pharma

Business Honor
02 October, 2025

The acquisition strengthens Indegene’s data-driven marketing capabilities for global pharmaceutical clients.

BioPharm Communications is a healthcare marketing business based on Pennsylvania and has been acquired by Indegene which is a digital technology company that focuses in life sciences commercialization. The goal of this attainment is to strengthen Indegene's marketing capabilities and powered by AI in advertising technologies for multinational pharmaceutical businesses.

Through Indegene's US subsidiary ILSL Inc., the agreement will bring together Indegene's data and analytics systems with BioPharm's precision marketing capabilities. The acquisition's financial specifics were not disclosed. BioPharm had access to more than three million healthcare decision makers as a member of Omnicom Health Group prior to joining Indegene. 17 of the top 25 biopharmaceutical firms in the world have collaborated with BioPharm since its establishment in 2005.

The firm is famous for producing engagement that is driven by data, media strategy, and focused marketing campaigns. It is expected that this acquisition will support Indegene to provide pharmaceutical businesses dealing with complicated commercialization difficulties with more mountable and quantifiable marketing solutions. The acquisition improves Indegene's standing as a tech-focused partner for life sciences companies, according to Manish Gupta, CEO of Indegene, who also commended BioPharm's impressive expansion.

The combination comes at a hazardous moment, according to BioPharm President Steve Carickhoff, who also stressed how Indegene's AI capabilities will open up new avenues for offering customers more value. In order to increase media returns on investment and establish more efficient marketing operations, Indegene and BioPharm intend to merge their data and technologies. Seyfarth Shaw LLP provided legal help for the acquisition. Capital Research, Fidelity International, Premji Invest, and a number of mutual funds are among Indigene's principal investors.